化学原料药
(C060201.国证.三级)A股通融
(
市盈率
46.57
市净率
2.506
股息率
1.24%
)·市值加权
发布时间2011-01-04样本数47市值3,310.14亿元A股市值3,277.69亿元流通市值2,743.91亿元自由流通市值1,800.96亿元陆股通持仓金额占市值比例1.18% (39.91亿元2025-09-30) 融资融券余额占市值比例2.96% (融资余额97.67亿元融券余额2,398.25万元2025-12-09) 行业估值数据计算说明文档行业财务数据计算说明文档
二级:制药 (C0602)
(
市盈率
38.45
市净率
2.639
股息率
1.65%
)·市值加权
一级:医药卫生 (C06)
(
市盈率
49.74
市净率
3.010
股息率
1.34%
)·市值加权
关注
283
发表讨论

化学原料药(C060201).国证 - 样本列表

最后更新于：2025-12-09

# 公司名称 市值市盈率市净率股息率涨跌幅今年以来投资收益率公司性质财报日期公告时间营业总收入归属于母公司普通股股东的净利润归属于母公司普通股股东的加权ROE
累积同比累积同比累积同比
1川宁生物通
301301.sz		229.03亿元24.472.8902.63%-0.19%-11.59%自然人2025-Q32025-10-2834.36亿元-22.90%6.11亿元-43.17%7.63%-7.12%
关注
119
2博瑞医药通
688166.sh		218.91亿元352.649.1720.19%-0.63%71.61%自然人2025-Q32025-10-318.74亿元-10.50%0.50亿元-71.64%2.01%-5.36%
关注
247
3普洛药业通
000739.sz		184.54亿元21.412.8454.40%-1.42%2.66%集体2025-Q32025-10-2277.64亿元-16.43%7.00亿元-19.48%10.21%-3.31%
关注
958
4九洲药业通
603456.sh		162.77亿元22.521.8592.71%-0.71%37.99%自然人2025-Q32025-10-1641.60亿元4.92%7.48亿元18.51%8.57%1.17%
关注
635
5皓元医药通
688131.sh		153.77亿元52.145.1230.32%-2.49%104.04%自然人2025-Q32025-10-3120.59亿元27.18%2.37亿元65.09%7.92%2.43%
关注
173
6浙江医药通
600216.sh		133.28亿元10.711.2062.64%-0.72%-10.47%自然人2025-Q32025-10-2866.95亿元-5.87%9.33亿元9.83%8.49%0.02%
关注
557
7国邦医药通
605507.sh		132.22亿元15.151.5982.53%-1.66%16.92%自然人2025-Q32025-10-1744.70亿元1.17%6.70亿元15.78%8.24%0.61%
关注
93
8东诚药业通
002675.sz		120.89亿元72.792.7640.55%-0.95%20.22%自然人2025-Q32025-10-2920.43亿元-5.52%1.49亿元-10.64%3.37%-0.09%
关注
423
9ST诺泰通
688076.sh		119.72亿元24.013.8501.50%1.15%3.60%自然人2025-Q32025-10-2315.27亿元21.95%4.45亿元26.92%15.41%0.78%
关注
153
10新华制药通
000756.sz		114.78亿元30.032.2291.50%-0.36%7.46%国有2025-Q32025-10-2567.63亿元0.42%2.56亿元-25.53%5.01%-2.20%
关注
319
11海翔药业通
002099.sz		101.33亿元-30.251.9790%-0.32%21.32%自然人2025-Q32025-10-2913.67亿元-5.39%0.07亿元-39.15%0.14%-0.08%
关注
318
12向日葵通
300111.sz		92.94亿元1,463.9713.5150%-3.86%122.84%自然人2025-Q32025-10-282.00亿元-12.09%0.01亿元-53.10%0.13%-0.28%
关注
138
13奥锐特通
605116.sh		89.77亿元21.153.5591.31%-0.76%6.12%自然人2025-Q32025-10-3112.37亿元13.67%3.54亿元24.58%14.37%0.62%
关注
185
14天宇股份通
300702.sz		85.05亿元44.352.2860.20%-1.29%46.99%自然人2025-Q32025-10-3022.87亿元18.36%2.21亿元159.57%6.12%3.69%
关注
417
15奥翔药业通
603229.sh		80.12亿元43.353.4131.03%-0.31%-2.37%自然人2025-Q32025-10-316.46亿元-6.40%2.07亿元-9.59%8.86%-1.29%
关注
231
16花园生物通
300401.sz		77.93亿元25.822.4660.79%0.63%-1.44%自然人2025-Q32025-10-189.36亿元-0.20%2.34亿元-3.07%7.09%-0.91%
关注
557
17富祥药业通
300497.sz		77.73亿元-28.493.6180%-2.70%73.02%自然人2025-Q32025-10-287.69亿元-21.24%-0.63亿元-1.09%-2.92%-0.39%
关注
4716
18尔康制药通
300267.sz		75.29亿元-24.421.6840%-4.45%31.29%自然人2025-Q32025-10-3010.06亿元17.81%0.40亿元255.40%0.89%1.43%
关注
256
19兄弟科技通
002562.sz		73.71亿元67.192.0030%-1.07%51.76%自然人2025-Q32025-10-3127.25亿元4.84%1.01亿元211.75%3.22%2.19%
关注
303
20宏源药业通
301246.sz		69.72亿元490.211.6080.17%-1.41%29.07%自然人2025-Q32025-10-2313.17亿元-0.39%-0.01亿元-103.04%-0.03%-0.86%
关注
31
21亨迪药业通
301211.sz		56.71亿元149.952.5101.27%-2.65%-6.10%自然人2025-Q32025-10-283.19亿元-4.52%0.21亿元-71.96%0.92%-2.29%
关注
57
22昊帆生物通
301393.sz		54.14亿元39.532.3190.79%-0.77%26.54%自然人2025-Q32025-10-294.35亿元32.47%0.99亿元3.01%4.30%-0.02%
关注
46
23键凯科技通
688356.sh		49.89亿元131.613.8440.18%-2.11%44.77%自然人2025-Q32025-10-312.11亿元13.47%0.41亿元24.72%3.17%0.62%
关注
193
24新天地通
301277.sz		47.48亿元38.383.1192.36%-1.46%25.56%自然人2025-Q32025-10-224.81亿元-10.42%0.92亿元-35.19%6.02%-3.31%
关注
51
25津药药业通
600488.sh		46.51亿元285.451.5392.30%-1.16%2.76%2025-Q32025-10-2922.32亿元-13.24%0.70亿元-62.75%2.25%-3.96%
关注
139
26永安药业通
002365.sz		46.03亿元181.172.3290.63%-1.26%96.19%自然人2025-Q32025-10-305.77亿元-6.72%0.25亿元-58.78%1.28%-1.81%
关注
230
27新森萱医药通
920946.bj		45.85亿元33.703.7001.30%-2.36%23.30%2025-Q32025-10-294.11亿元5.90%1.04亿元13.45%8.51%0.58%
关注
51
28美诺华通
603538.sh		44.48亿元44.711.9790.25%-1.56%59.01%自然人2025-Q32025-10-2811.17亿元17.67%0.96亿元51.66%4.26%1.30%
关注
332
29北大医药通
000788.sz		42.73亿元29.762.6460.84%0.42%20.59%自然人2025-Q32025-10-3112.31亿元-19.76%1.36亿元4.31%8.63%-0.17%
关注
181
30司太立通
603520.sh		42.53亿元-145.391.6351.55%-1.32%13.16%自然人2025-Q32025-10-3118.45亿元2.24%0.29亿元221.14%1.10%0.69%
关注
400
31拓新药业通
301089.sz		39.89亿元-84.162.6200%-1.81%11.81%自然人2025-Q32025-10-292.72亿元-16.64%-0.30亿元-10.37倍-1.96%-1.79%
关注
94
32海森药业通
001367.sz		34.37亿元27.762.3940.51%-0.79%23.27%自然人2025-Q32025-10-223.59亿元12.13%0.88亿元1.45%6.35%-0.46%
关注
47
33同和药业通
300636.sz		33.72亿元35.681.4190.50%-0.12%1.29%自然人2025-Q32025-10-256.36亿元11.63%0.84亿元-12.61%3.56%-0.66%
关注
164
34圣达生物通
603079.sh		32.78亿元53.662.0800%-1.81%28.73%自然人2025-Q32025-10-306.21亿元2.04%0.53亿元146.04%3.88%2.15%
关注
262
35山河药辅通
300452.sz		32.40亿元25.013.4732.15%-1.85%17.02%自然人2025-Q32025-10-216.97亿元8.09%1.33亿元8.28%13.69%-0.12%
关注
420
36富士莱通
301258.sz		29.90亿元39.371.5640.28%-0.67%38.51%自然人2025-Q32025-10-243.23亿元3.23%0.73亿元430.16%3.83%3.11%
关注
71
37科源制药通
301281.sz		29.89亿元57.222.1800.72%-1.60%-7.15%自然人2025-Q32025-10-243.03亿元-8.52%0.31亿元-20.69%2.30%-0.68%
关注
26
38河化股份通
000953.sz		29.51亿元373.6719.1450%9.96%44.19%自然人2025-Q32025-10-281.29亿元-22.34%0.08亿元-89.99%5.30%-69.74%
关注
109
39赛托生物通
300583.sz		27.77亿元-16.081.5730.14%-1.74%-25.02%自然人2025-Q32025-10-297.49亿元-2.07%-0.69亿元-570.46%-3.84%-4.58%
关注
89
40广济药业通
000952.sz		27.36亿元-11.692.8340%-5.85%27.67%国有2025-Q32025-10-274.29亿元-7.12%-0.97亿元38.64%-9.54%2.81%
关注
196
41共同药业通
300966.sz		23.77亿元-51.833.0680%-1.15%27.84%自然人2025-Q32025-10-284.55亿元24.54%-0.32亿元-129.02%-3.61%-2.11%
关注
73
42东亚药业通
605177.sh		22.26亿元-10.201.3090%-0.77%-1.52%自然人2025-Q32025-10-315.96亿元-38.08%-0.72亿元-260.31%-3.93%-6.17%
关注
86
43新无锡晶海通
920547.bj		18.18亿元34.462.6140.85%-2.05%50.67%2025-Q32025-10-272.93亿元15.69%0.48亿元25.93%7.07%1.03%
关注
18
44新海昇药业通
920656.bj		16.93亿元25.472.4801.18%-1.97%37.06%2025-Q32025-10-271.64亿元40.89%0.49亿元47.16%7.33%1.74%
关注
21
45新新赣江通
920367.bj		14.71亿元140.833.0951.20%-2.63%48.11%2025-Q32025-10-300.97亿元-12.69%0.08亿元-59.02%1.75%-2.50%
关注
19
46新峆一药业通
920478.bj		14.38亿元24.702.8161.56%-3.28%54.67%2025-Q32025-10-282.11亿元7.12%0.46亿元22.85%9.06%1.06%
关注
23
47新欧康医药通
920230.bj		12.47亿元177.573.0570.62%-2.29%15.65%2025-Q32025-10-302.10亿元-6.15%0.04亿元-78.97%1.00%-3.84%
关注
18

©2016-2024 理杏仁 | 北京乾谦慧科技有限公司 | 违法和不良信息举报中心 互联网违法和不良信息投诉：010-86460785

推荐Chrome浏览器 | 京公网安备11010502033936号 | 京B2-20201471 | 京ICP备16057978号 | 用户协议

风险提示: 本站所有免费及收费信息和数据仅供参考，不构成投资建议，理杏仁不承担由此导致的任何法律责任。